Takeda Pharmaceutical (TAK) Cash & Current Investments (2017 - 2026)

Takeda Pharmaceutical's Cash & Current Investments history runs 10 years deep, the most recent figure standing at $4.1 billion for Q1 2026.

• On a quarterly basis, Cash & Current Investments rose 52.78% year-over-year to $4.1 billion in Q1 2026; TTM through Mar 2026 was $4.1 billion, a 52.78% increase from a year earlier, with the FY2026 full-year figure at $4.2 billion, up 58.92% from the prior year.
• Cash & Current Investments retreated to $4.1 billion in Q1 2026 per TAK's latest filing, from $7.0 billion in the prior quarter.
• Across five years, Cash & Current Investments topped out at $8.2 billion in Q3 2022 and bottomed at $2.7 billion in Q1 2025.
• The 5-year median for Cash & Current Investments is $5.9 billion (2024), against an average of $5.7 billion.
• Across the five-year window, Cash & Current Investments sank 46.43% in 2023 and jumped 71.87% in 2024, its largest moves.
• Year by year, Cash & Current Investments stood at $6.8 billion in 2022, then plunged by 44.46% to $3.8 billion in 2023, then soared by 55.37% to $5.9 billion in 2024, then grew by 19.53% to $7.0 billion in 2025, then sank by 42.07% to $4.1 billion in 2026.
• Per Business Quant, the three latest TAK Cash & Current Investments figures stand at $4.1 billion (Q1 2026), $7.0 billion (Q4 2025), and $7.1 billion (Q3 2025).